128 related articles for article (PubMed ID: 8293414)
1. Carcinoembryonic antigen-like reactivity in malignant mesothelioma. A comparison between different commercially available antibodies.
Dejmek A; Hjerpe A
Cancer; 1994 Jan; 73(2):464-9. PubMed ID: 8293414
[TBL] [Abstract][Full Text] [Related]
2. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
Sheibani K; Battifora H; Burke JS
Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
[TBL] [Abstract][Full Text] [Related]
3. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis.
Dejmek A; Hjerpe A
Cytopathology; 2000 Feb; 11(1):8-17. PubMed ID: 10714371
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
Szpak CA; Johnston WW; Roggli V; Kolbeck J; Lottich SC; Vollmer R; Thor A; Schlom J
Am J Pathol; 1986 Feb; 122(2):252-60. PubMed ID: 2418688
[TBL] [Abstract][Full Text] [Related]
5. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma.
Attanoos RL; Goddard H; Gibbs AR
Histopathology; 1996 Sep; 29(3):209-15. PubMed ID: 8884348
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: a stepwise logistic regression analysis.
Dejmek A; Hjerpe A
APMIS; 1994 Apr; 102(4):255-64. PubMed ID: 8011302
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases.
Otis CN; Carter D; Cole S; Battifora H
Am J Surg Pathol; 1987 Jun; 11(6):445-56. PubMed ID: 2438954
[TBL] [Abstract][Full Text] [Related]
8. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry in the diagnosis of malignant mesothelioma.
Pfaltz M; Odermatt B; Christen B; Rüttner JR
Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887
[TBL] [Abstract][Full Text] [Related]
10. Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies.
Sheahan K; O'Brien MJ; Burke B; Dervan PA; O'Keane JC; Gottlieb LS; Zamcheck N
Am J Clin Pathol; 1990 Aug; 94(2):157-64. PubMed ID: 1695478
[TBL] [Abstract][Full Text] [Related]
11. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma.
Brockstedt U; Gulyas M; Dobra K; Dejmek A; Hjerpe A
Am J Clin Pathol; 2000 Aug; 114(2):203-9. PubMed ID: 10941335
[TBL] [Abstract][Full Text] [Related]
12. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
13. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma.
Sheibani K; Shin SS; Kezirian J; Weiss LM
Am J Surg Pathol; 1991 Aug; 15(8):779-84. PubMed ID: 2069213
[TBL] [Abstract][Full Text] [Related]
14. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
Ordóñez NG
Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin.
Duggan MA; Masters CB; Alexander F
Acta Cytol; 1987; 31(6):807-14. PubMed ID: 2447718
[TBL] [Abstract][Full Text] [Related]
16. Carcinoembryonic antigen in pleural effusions. Diagnostic value in malignant mesothelioma.
Faravelli B; D'Amore E; Nosenzo M; Betta PG; Donna A
Cancer; 1984 Mar; 53(5):1194-7. PubMed ID: 6362839
[TBL] [Abstract][Full Text] [Related]
17. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
Ordóñez NG
Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
Abutaily AS; Addis BJ; Roche WR
J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
[TBL] [Abstract][Full Text] [Related]
19. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
al-Saffar N; Hasleton PS
Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
[TBL] [Abstract][Full Text] [Related]
20. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE
Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
